Methylation of the ATM promoter in glioma cells alters ionizing radiation sensitivity

Biochemical and Biophysical Research Communications

Volumn 344, Issue 3, 2006, Pages 821-826

  Roy, Kanaklata ^a   Wang, Lilin ^a   Makrigiorgos, G Mike ^a   Price, Brendan D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ATM; Glioblastoma; Ionizing radiation; Methylation; Radiation therapy; Radiosensitivity

Indexed keywords

ATM PROTEIN; AZACITIDINE;

ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; DEMETHYLATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IONIZING RADIATION; METHYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; STATISTICAL SIGNIFICANCE;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, RADIATION; GLIOMA; HUMANS; METHYLATION; PROMOTER REGIONS (GENETICS); PROTEIN-SERINE-THREONINE KINASES; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION, IONIZING; TUMOR SUPPRESSOR PROTEINS;

EID: 33646491424     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.222     Document Type: Article

References (33)

1. Taylor A.M., and Byrd P.J. Molecular pathology of ataxia telangiectasia. J. Clin. Pathol. 58 (2005) 1009-1015
2. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3 (2003) 155-168
3. Lavin M.F., Birrell G., Chen P., Kozlov S., Scott S., and Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat. Res. 569 (2005) 123-132
4. Bakkenist C.J., and Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 (2003) 499-506
5. Pandita T.K., Pathak S., and Geard C.R. Chromosome end associations, telomeres and telomerase activity in ataxia telangiectasia cells. Cytogenet. Cell Genet. 71 (1995) 86-93
6. Allio T., and Preston R.J. Increased sensitivity to chromatid aberration induction by bleomycin and neocarzinostatin results from alterations in a DNA damage response pathway. Mutat. Res. 453 (2000) 5-15
7. MacLeod R.A., Buchheim T., Kaufmann M., and Drexler H.G. Chromosomal breakage correlates with delayed lethality in normal and ataxia telangiectasia cell lines treated with bleomycin. Mutat. Res. 372 (1996) 33-42
8. Jeggo P.A., Carr A.M., and Lehmann A.R. Splitting the ATM: distinct repair and checkpoint defects in ataxia-telangiectasia. Trends Genet. 14 (1998) 312-316
9. Bernstein J.L., Teraoka S., Haile R.W., Borresen-Dale A.L., Rosenstein B.S., Gatti R.A., Diep A.T., Jansen L., Atencio D.P., Olsen J.H., Bernstein L., Teitelbaum S.L., Thompson W.D., and Concannon P. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum. Mutat. 21 (2003) 542-550
10. Thorstenson Y.R., Roxas A., Kroiss R., Jenkins M.A., Yu K.M., Bachrich T., Muhr D., Wayne T.L., Chu G., Davis R.W., Wagner T.M., and Oefner P.J. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 63 (2003) 3325-3333
11. Gumy-Pause F., Wacker P., and Sappino A.P. ATM gene and lymphoid malignancies. Leukemia 18 (2004) 238-242
12. Boultwood J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J. Clin. Pathol. 54 (2001) 512-516
13. Baylin S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2 Suppl 1 (2005) S4-S11
14. Costello J.F., Berger M.S., Huang H.S., and Cavenee W.K. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 56 (1996) 2405-2410
15. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., and Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92 (2000) 564-569
16. Kane M.F., Loda M., Gaida G.M., Lipman J., Mishra R., Goldman H., Jessup J.M., and Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57 (1997) 808-811
17. Ai L., Vo Q.N., Zuo C., Li L., Ling W., Suen J.Y., Hanna E., Brown K.D., and Fan C.Y. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 150-156
18. Kim W.J., Vo Q.N., Shrivastav M., Lataxes T.A., and Brown K.D. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene 21 (2002) 3864-3871
19. Sun Y., Jiang X., Chen S., Fernandes N., and Price B.D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc. Natl. Acad. Sci. USA 102 (2005) 13182-13187
20. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93 (1996) 9821-9826
21. Osborn M., Ludwig-Festl M., Weber K., Bignami A., Dahl D., and Bayreuther K. Expression of glial and vimentin type intermediate filaments in cultures derived from human glial material. Differentiation 19 (1981) 161-167
22. Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K., Rotman G., Smith S., Chessa L., Jorgensen T.J., Harnik R., Frydman M., Sanal O., Portnoi S., Goldwicz Z., Jaspers N.G., Gatti R.A., Lenoir G., Lavin M.F., Tatsumi K., Wegner R.D., Shiloh Y., and Bar-Shira A. Predominance of null mutations in ataxia-telangiectasia. Hum. Mol. Genet. 5 (1996) 433-439
23. Scott S.P., Bendix R., Chen P., Clark R., Dork T., and Lavin M.F. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc. Natl. Acad. Sci. USA 99 (2002) 925-930
24. Turenne G.A., Paul P., Laflair L., and Price B.D. Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53. Oncogene 20 (2001) 5100-5110
25. Tribius S., Pidel A., and Casper D. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001) 511-523
26. Vo Q.N., Kim W.J., Cvitanovic L., Boudreau D.A., Ginzinger D.G., and Brown K.D. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene 23 (2004) 9432-9437
27. Beamish H., and Lavin M.F. Radiosensitivity in ataxia-telangiectasia: anomalies in radiation-induced cell cycle delay. Int. J. Radiat. Biol. 65 (1994) 175-184
28. Beamish H., Khanna K.K., and Lavin M.F. Ionizing radiation and cell cycle progression in ataxia telangiectasia. Radiat. Res. 138 (1994) S130-S133
29. Chen S., Wang G., Makrigiorgos G.M., and Price B.D. Stable siRNA-mediated silencing of ATM alters the transcriptional profile of HeLa cells. Biochem. Biophys. Res. Commun. 317 (2004) 1037-1044
30. Herzog K.H., Chong M.J., Kapsetaki M., Morgan J.I., and McKinnon P.J. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 280 (1998) 1089-1091
31. Chong M.J., Murray M.R., Gosink E.C., Russell H.R., Srinivasan A., Kapsetaki M., Korsmeyer S.J., and McKinnon P.J. Atm and Bax cooperate in ionizing radiation-induced apoptosis in the central nervous system. Proc. Natl. Acad. Sci. USA 97 (2000) 889-894
32. Gosink E.C., Chong M.J., and McKinnon P.J. Ataxia telangiectasia mutated deficiency affects astrocyte growth but not radiosensitivity. Cancer Res. 59 (1999) 5294-5298
33. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., and Cavenee W.K. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61 (2002) 215-225 discussion 226-229